Baxter International (BAX) has been on a tear, going into its third straight week with a solid advance and good volume on news that it will finally split itself in two. The company announced a year ago that it would spin off its bioscience division, but the board of directors approved the move only on June 5. On June 9 after the close, the company announced SEC approval. It touched off the rally the next day.